IL-27 suppresses RANKL expression in CD4+ T cells in part through STAT3

Area of Science:

• Immunology
• Molecular Biology
• Bone Biology

Background:

• Receptor activator of NF-κB ligand (RANKL) is crucial in bone-destructive diseases like rheumatoid arthritis.
• IL-27 is a cytokine that modulates T cell differentiation and inflammatory responses.
• Previous studies show IL-27 inhibits osteoclastogenesis and ameliorates bone destruction.

Purpose of the Study:

• To investigate the effect of IL-27 on RANKL expression in CD4(+) T cells.
• To understand the role of IL-27 in regulating RANKL production by T cells.

Main Methods:

• Investigated IL-27's impact on cell surface and soluble RANKL expression in activated naive CD4(+) T cells.
• Analyzed the involvement of STAT1, STAT3, and IL-10 in IL-27's inhibitory mechanism.
• Compared IL-27's effect on RANKL expression in naive CD4(+) T cells versus differentiated Th17 cells.

Main Results:

• IL-27 significantly inhibited both cell surface and soluble RANKL expression in naive CD4(+) T cells upon activation.
• The inhibitory effect of IL-27 on RANKL was partly mediated by STAT3, but not by STAT1 or IL-10.
• IL-27 showed a less pronounced inhibitory effect on RANKL expression in pre-differentiated Th17 cells.

Conclusions:

• IL-27 effectively suppresses primary RANKL expression in CD4(+) T cells.
• This suppression of RANKL by IL-27 may contribute to its therapeutic potential in reducing inflammatory bone destruction.